Mirum Pharmaceuticals, Inc. (MIRM) Stock Grade

About Mirum Pharmaceuticals, Inc.'s fundamentals

Mirum Pharmaceuticals is a biotech company with a $4.0 billion market cap that has demonstrated strong revenue momentum, growing 54.7% year-over-year. Despite this growth, the company operates at a net loss with a -4.5% net margin, reflecting the typical cost structure of developing pharmaceutical products. A notable positive signal is that the company maintains positive free cash flow despite its accounting losses, suggesting the business is generating cash even as it invests in operations and development. The company does not pay a dividend, which is consistent with a growth-stage biotech focused on reinvesting capital.